12/2
07:00 am
ktta
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Medium
Report
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
11/28
09:20 am
ktta
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
High
Report
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
11/25
07:00 am
ktta
Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS
High
Report
Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS
11/24
07:00 am
ktta
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data
High
Report
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data
11/21
12:35 pm
ktta
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
High
Report
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
11/20
04:01 pm
ktta
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study
High
Report
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study
11/18
01:18 pm
ktta
Pasithea Therapeutics (NASDAQ:KTTA) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Pasithea Therapeutics (NASDAQ:KTTA) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
11/7
01:14 am
ktta
Pasithea Therapeutics (NASDAQ:KTTA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Pasithea Therapeutics (NASDAQ:KTTA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/4
07:03 am
ktta
Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
Medium
Report
Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
9/16
07:03 am
ktta
Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
Medium
Report
Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
9/8
07:01 am
ktta
Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
Medium
Report
Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients